Discussion
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf), a first-in-class treatment for heavily pretreated adults with…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
The U.S. Food and Drug Administration (FDA) has given Celyad Oncology permission to begin a Phase 1 clinical trial of CYAD-211, an…
Discussion
A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s belantamab mafodotin, in combination with SpringWorks Therapeutics’ nirogacestat, in people with relapsed or…
Discussion
GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approval in the European Union, by the Committee for Medicinal Products for Human…
Discussion
A new research project aiming to better understand how fat cells help multiple myeloma cells resist treatment has won a $1.9 million grant from…
Discussion
A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or death in people with relapsed or…
